FreightTech innovator GenLogs has closed a $60 million Series B round led by Battery Ventures. The startup, founded by a former CIA officer, leverages a vast sensor network and AI to bring unprecedented visibility and security to the fragmented trucking industry.
JPMorgan raises its price target for Celsius Holdings (CELH) to $77, citing upside potential from its deepening PepsiCo partnership and the expanding distribution of its Alani Nu brand ahead of Q4 earnings.
Analyst Piper Sandler has lowered its price target on Black Diamond Therapeutics (BDTX) while maintaining an Overweight rating, following a broad review of its biotech coverage. The adjustment comes even as the company recently reported encouraging Phase 2 data for its lead oncology drug candidate.
Barclays initiates coverage with an Overweight rating and $20 price target on Altimmune, citing strong fundamentals and pipeline potential. The biotech firm prepares to channel recent offering proceeds toward its pivotal Phase 3 development for metabolic liver disease treatment pemvidutide.
Despite promising mid-stage clinical data and billion-dollar sales potential for its mRNA pipeline, Arcturus Therapeutics (ARCT) is trading near its cash value—a signal the market is assigning near-zero odds to its success. This stark disconnect has analysts debating whether the biotech firm is a glaring mispricing or a high-risk bet.
Advance Auto Parts (NYSE:AAP) remains a favored pick among hedge funds, even as Wall Street analysts offer conflicting price targets and ratings ahead of anticipated 2026 demand growth.
A suspected human smuggler with a prior conviction was shot by federal agents near the Arizona-Mexico border after allegedly firing at a CBP helicopter and agents during a foot pursuit, according to law enforcement officials.
A federal appeals court has dismissed a Justice Department misconduct complaint against U.S. District Judge James Boasberg, ruling the government failed to substantiate its allegations regarding the judge's public comments.
Garrett Motion (GTX) is drawing strong buy ratings from analysts, with a median price target suggesting over 20% upside, driven by its strategic pivot to zero-emission vehicle technologies and resilient financial profile.
H.C. Wainwright maintains a Buy rating on Lexeo Therapeutics but slashes its price target, citing persistent market doubts over the company's PKP2 cardiomyopathy program despite encouraging early clinical results.
Analysts maintain a bullish outlook on Goodyear Tire & Rubber, citing strong potential in the replacement tire market and favorable inventory trends, with a median price target suggesting a 7% upside.
Aptiv PLC sees mixed but upwardly revised price targets from major analysts, with Piper Sandler upgrading the auto tech supplier to Overweight and naming it a top pick for 2026, citing its pragmatic strategy and attractive valuation.
Despite a recent sales miss, AutoZone (AZO) is doubling down on store growth, drawing mixed analyst reactions. JPMorgan remains bullish with an $4,100 price target, while Wolfe Research downgraded the stock, highlighting the complex landscape for the auto parts retailer.
Barclays initiates coverage of 4D Molecular Therapeutics with an Overweight rating and a $33 price target, citing a favorable industry backdrop with potential M&A tailwinds and shifting focus away from drug pricing pressures. The gene therapy developer also outlined key clinical milestones expected through 2026.
Alibaba's logistics arm Cainiao is making a major strategic move into autonomous freight, with a reported $2 billion investment in L4 self-driving truck firm Zelos Technology, signaling a deepening push into AI-driven supply chain solutions.
Morgan Stanley has upgraded Johnson & Johnson to 'Overweight,' raising its price target to $262, citing confidence in the healthcare giant's robust pipeline of new pharmaceuticals and medical devices.
The FlexShares Quality Dividend Index Fund (QDF) promises steady income through quality screens, but its substantial allocation to technology stocks—making up one-third of the portfolio—may reshape risk expectations for investors, particularly retirees seeking stability.
As tech giants design their own AI processors, Broadcom's design expertise and TSMC's manufacturing might are creating a lucrative second front in the semiconductor boom, diversifying the winners beyond the GPU market leader.
Wall Street's top analysts made waves Monday with revised ratings on key stocks, highlighting a growing divergence in tech and retail outlooks as earnings season approaches.
While Apis Capital's flagship fund posted stellar 2025 returns, its latest investor letter spotlights the ongoing divergence of opinion on AI pure-plays like C3.ai, where heavy investment needs clash with market expectations for profitability.
